ArticleJournal of orthopaedic case reports2026
Fat Embolism Syndrome: A Case Series from a Single Tertiary Care Hospital.
Article in Journal of orthopaedic case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Fat embolism syndrome (FES) is a rare but potentially fatal complication predominantly affecting young adults following long bone fractures. No definitive diagnostic test exists; diagnosis remains one of exclusion based on Gurd's criteria. Early recognition before the syndrome becomes fully established is critical to reduce preventable mortality. Materials and Methods: We report a case series of six patients diagnosed with FES between 2020 and 2025, examining their clinical and laboratory parameters, including injury severity score, number of fractures, interleukin-6 (IL-6), C-reactive protein (CRP), hemoglobin (Hb), platelet count, and neurological status in relation to FES development. We charted the key parameters to depict the natural history of FES. Results: All six patients were young adults (age 21-32 years) who sustained long bone fractures following road traffic accidents. All developed hypoxia and neurological deterioration (Glasgow coma scale drop) within days. Serum IL-6 and CRP were elevated in all patients for whom these were measured. All patients showed a fall in Hb and thrombocytopenia. Petechiae were present in 4/6 cases (67%). Two patients died (33%); both had high injury burden and markedly elevated IL-6. Conclusion: Hypoxia and elevated IL-6 appear to be the earliest detectable indicators of evolving FES, preceding the full clinical syndrome. Acute anemia, thrombocytopenia, hypoalbuminemia, and oliguria were common. Only after the disease is clinically advanced Gurd's criteria were fulfilled. Rapid fracture stabilisation, continuous SpO2 monitoring, serial IL-6 measurement, and universal team awareness are essential strategies for its potential prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.